checkAd

     128  0 Kommentare Zogenix Presents New Data for FINTEPLA in Dravet Syndrome at CNS 2020 - Seite 3

    CONTACTS:

    Zogenix
    Melinda Baker
    Senior Director, Corporate Communications
    +1 (510) 788-8732
    corpcomms@zogenix.com

    Investors
    Brian Ritchie
    Managing Director, LifeSci Advisors LLC
    +1 (212) 915-2578
    britchie@lifesciadvisors.com

    Lesen Sie auch

    Media
    Stefanie Tuck
    Vice President, Porter Novelli
    +1 (978) 390-1394
    stefanie.tuck@porternovelli.com



    globenewswire
    0 Follower
    Autor folgen
    RSS-Feed abonnieren

    Weitere Artikel des Autors

    Seite 3 von 3

    Verfasst von globenewswire
    1 im Artikel enthaltener WertIm Artikel enthaltene Werte
    Zogenix Presents New Data for FINTEPLA in Dravet Syndrome at CNS 2020 - Seite 3 Interim data from open-label extension trial showed substantial seizure reductions were maintained in patients treated with FINTEPLA for up to two years Post-hoc analysis demonstrated NNTs (Number Needed to Treat) to achieve a clinically meaningful …